The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic
Abstract
Expanded polyglutamine (polyQ) repeats cause neurodegenerative disorders, but their cytotoxic structures remain to be elucidated. Although soluble polyQ oligomers have been proposed as a cytotoxic structure, the cytotoxicity of soluble polyQ oligomers, not inclusion bodies (IBs), has not been proven in living cells. To clarify the cytotoxicity of soluble polyQ oligomers, we carried our fluorescence resonance energy transfer (FRET) confocal microscopy and distinguished oligomers from monomers and IBs in a single living cell. FRET signals were detected when donor and acceptor fluorescent proteins were attached to the same side, not the opposite side, of polyQ repeats, which agrees with a parallel beta-sheet or a head-to-tail cylindrical beta-sheet model. These FRET signals disappeared in semi-intact cells, indicating that these polyQ oligomers are soluble. PolyQ monomers assembled into soluble oligomers in a length-dependent manner, which was followed by the formation of IBs. Notably, survival assay of neuronally differentiated cells revealed that cells with soluble oligomers died faster than those with IBs or monomers. These results indicate that a length-dependent formation of oligomers is an essential mechanism underlying neurodegeneration in polyQ-mediated disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“In many neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, soluble oligomers of causative proteins have been proposed to be the cytotoxic structure (23,43).”
BackgroundCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Partitioning of Lipid-Modified Monomeric GFPs into Membrane Microdomains of Live Cells
Zacharias, D. A., Violin, J. D., Newton, A. C., & Tsien, R. Y. (2002) · Science · doi:10.1126/science.1068539 · Cited by 2,235
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.
Perutz, M. F., Johnson, T., Suzuki, M., & Finch, J. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5355 · Cited by 1,062
Modulation of neurodegeneration by molecular chaperones
Muchowski, P. J., & Wacker, J. L. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1587 · Cited by 1,024
Ataxin-1 Nuclear Localization and Aggregation
Klement, I. A., Skinner, P. J., Kaytor, M. D., Yi, H., Hersch, S. M., Clark, H. B., Zoghbi, H. Y., & Orr, H. T. (1998) · Cell · doi:10.1016/s0092-8674(00)81781-x · Cited by 956
Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors.
Adam, S. A., Marr, R. S., & Gerace, L. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.3.807 · Cited by 896
Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Ceña, V., Gallego, C., & Comella, J. X. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750991.x · Cited by 820
Diseases of Unstable Repeat Expansion: Mechanisms and Common Principles
Gatchel, J. R., & Zoghbi, H. Y. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1691 · Cited by 794
What is the role of protein aggregation in neurodegeneration?
Ross, C. A., & Poirier, M. A. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1742 · Cited by 604
Xia, Z., & Liu, Y. (2001) · Biophysical Journal · doi:10.1016/s0006-3495(01)75886-9 · Cited by 518
Amyloid fibers are water-filled nanotubes
Perutz, M. F., Finch, J. T., Berriman, J., & Lesk, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042681399 · Cited by 506
Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
Sánchez, I., Mahlke, C., & Yuan, J. (2003) · Nature · doi:10.1038/nature01301 · Cited by 503
Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein
Taylor, J. P. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg074 · Cited by 426
Cellular Toxicity of Polyglutamine Expansion Proteins
Schaffar, G., Breuer, P., Boteva, R., Behrends, C., Tzvetkov, N., Strippel, N., Sakahira, H., Siegers, K., Hayer-Hartl, M., & Hartl, F. U. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.029 · Cited by 425
Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization
Poirier, M. A., Li, H., Macosko, J., Cai, S., Amzel, M., & Ross, C. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205809200 · Cited by 367
Igarashi, S., Koide, R., Shimohata, T., Yamada, M., Hayashi, Y., Takano, H., Date, H., Oyake, M., Sato, T., Sato, A., et al. (1998) · Nature Genetics · doi:10.1038/ng0298-111 · Cited by 355
A toxic monomeric conformer of the polyglutamine protein
Nagai, Y., Inui, T., Popiel, H. A., Fujikake, N., Hasegawa, K., Urade, Y., Goto, Y., Naiki, H., & Toda, T. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1215 · Cited by 333
Self-citationKim, M., Lee, H.-S., LaForet, G., McIntyre, C., Martin, E. J., Chang, P., Kim, T. W., Williams, M., Reddy, P. H., Tagle, D., et al. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-03-00964.1999 · Cited by 305
Inefficient degradation of truncated polyglutamine proteins by the proteasome
Holmberg, C. I., Staniszewski, K. E., Mensah, K. N., Matouschek, A., & Morimoto, R. I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600426 · Cited by 289
Wacker, J. L., Zareie, M. H., Fong, H., Sarikaya, M., & Muchowski, P. J. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb860 · Cited by 283
Chaperonin TRiC Promotes the Assembly of polyQ Expansion Proteins into Nontoxic Oligomers
Behrends, C., Langer, C. A., Boteva, R., Böttcher, U. M., Stemp, M. J., Schaffar, G., Rao, B. V., Giese, A., Kretzschmar, H., Siegers, K., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.017 · Cited by 278
Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state
Kitamura, A., Kubota, H., Pack, C.-G., Matsumoto, G., Hirayama, S., Takahashi, Y., Kimura, H., Kinjo, M., Morimoto, R. I., & Nagata, K. (2006) · Nature Cell Biology · doi:10.1038/ncb1478 · Cited by 278
Brignull, H. R., Moore, F. E., Tang, S. J., & Morimoto, R. I. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0990-06.2006 · Cited by 211
Heiser, V., Engemann, S., Bröcker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182426599 · Cited by 205
Stereoselective Interactions of Peptide Inhibitors with the β-Amyloid Peptide
Chalifour, R. J., McLaughlin, R. W., Lavoie, L., Morissette, C., Tremblay, N., Boulé, M., Sarazin, P., Stéa, D., Lacombe, D., Tremblay, P., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212694200 · Cited by 177
The Two-stage Pathway of Ataxin-3 Fibrillogenesis Involves a Polyglutamine-independent Step
Ellisdon, A. M., Thomas, B., & Bottomley, S. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601470200 · Cited by 164
A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor
Pollitt, S. K., Pallos, J., Shao, J., Desai, U. A., Ma, A. A. K., Thompson, L. M., Marsh, J. L., & Diamond, M. I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00697-4 · Cited by 151
Nagai, Y. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg144 · Cited by 146
Self-citationPolyglutamine fibrillogenesis: The pathway unfolds
Ross, C. A., Poirier, M. A., Wanker, E. E., & Amzel, L. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237018100 · Cited by 138
Li, M., Chevalier-Larsen, E. S., Merry, D. E., & Diamond, M. I. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609972200 · Cited by 100
Moulder, K. L., Onodera, O., Burke, J. R., Strittmatter, W. J., & Johnson, E. M. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-02-00705.1999 · Cited by 94
Self-citationBiologically active molecules that reduce polyglutamine aggregation and toxicity
Desai, U. A., Pallos, J., Aye Aye, K., Stockwell, B. R., Thompson, L. M., Marsh, J., & Diamond, M. I. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl135 · Cited by 81
Onodera, O., Burke, J. R., Miller, S., Hester, S., Tsuji, S., Roses, A. D., & Strittmatter, W. J. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7337 · Cited by 66
Self-citationSinger, S. J., & Dewji, N. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509892103 · Cited by 57
Tanaka, M., Machida, Y., Nishikawa, Y., Akagi, T., Hashikawa, T., Fujisawa, T., & Nukina, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209852200 · Cited by 53
Cited by
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies
Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 507
Physicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs)
Theillet, F.-X., Binolfi, A., Frembgen-Kesner, T., Hingorani, K., Sarkar, M., Kyne, C., Li, C., Crowley, P. B., Gierasch, L., Pielak, G. J., et al. (2014) · Chemical Reviews · doi:10.1021/cr400695p · Cited by 503
Protein aggregates in Huntington's disease
Arrasate, M., & Finkbeiner, S. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.013 · Cited by 383
Polyglutamine neurodegeneration: protein misfolding revisited
Williams, A. J., & Paulson, H. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.07.004 · Cited by 341
Metadata
- Authors
- Takahashi, T., Kikuchi, S., Katada, S., Nagai, Y., Nishizawa, M., & Onodera, O.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-18
- Volume
- 17
- Issue
- 3
- Pages
- 345-356
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2162057703
- Cited by
- 258
- References
- 40
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.